Xilio Therapeutics, Inc. cotiza a 9.07 USD y tiene una capitalización bursátil de $60M. En los últimos 12 meses ha facturado $64M con un margen de flujo de caja libre del -12.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked…
| Periodo | 2026-08 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-0.33 | $-1.54 | $-2.24 | $-2.52 |
| Estimado | $-0.59 | $-0.42 | $-1.12 | $1.33 |
| Sorpresa | +44.1% | -266.7% | -100.0% | -289.5% |
| Métrica | XLO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -95.9% | -38.6% | -57.3% |
| Net Margin | -80.0% | -33.6% | -46.5% |
| FCF Margin | -12.6% | -13.9% | +1.3% |
| ROE | -99.3% | -40.4% | -58.9% |
| ROA | -22.6% | -32.0% | +9.4% |
| Current Ratio | 2.58 | 2.84 | -0.26 |
| Debt / Equity | — | 0.28 | — |